Skip to content

Study · Non-randomized trial · n = 135 · 2018

5 results

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE

Scandinavian journal of urology1 Oct 2018Cited by 17 (Europe PMC)

PMID30624128 (opens in a new tab)DOI10.1080/21681805.2018.1522372 (opens in a new tab)PepBankPUB-30624128
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients switching from leuprolide to degarelix, FSH was suppressed after crossover.

    In plain wordsIn prostate cancer patients switching from leuprolide to degarelix, FSH decreased after the switch.

    Peptide
    Degarelix
    Outcome
    DecreaseFSH after crossover
    Study

    n = 135

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 3 months after crossoverAs given in this study (human).

    Source sentences

    Summary
    Patients crossed-over from leuprolide to degarelix achieved a suppression of FSH and a significant PSA decrease.
    3 context sentences
    Summary · context
    In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
    Summary · context
    CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix.
    Summary · context
    PSA and FSH levels were evaluated in CS21A for 3 months after cross-over.
  2. 02HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients switching from leuprolide to degarelix, PSA decreased significantly after crossover.

    In plain wordsIn prostate cancer patients switching from leuprolide to degarelix, PSA decreased significantly after the switch.

    Peptide
    Degarelix
    Outcome
    DecreasePSA after crossover
    Study

    n = 135

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 3 months after crossoverAs given in this study (human).

    Source sentences

    Summary
    Patients crossed-over from leuprolide to degarelix achieved a suppression of FSH and a significant PSA decrease.
    3 context sentences
    Summary · context
    In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
    Summary · context
    CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix.
    Summary · context
    PSA and FSH levels were evaluated in CS21A for 3 months after cross-over.
  3. 03HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients, rapid PSA suppression persisted with degarelix in the comparative and extension studies.

    In plain wordsIn prostate cancer patients, PSA decreased rapidly and remained suppressed with degarelix.

    Peptide
    Degarelix
    Outcome
    DecreasePSA suppression
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Rapid PSA and FSH suppression was observed and maintained in the degarelix arm (CS21 and CS21A), while patients on leuprolide experienced rising PSA during CS21.
    3 context sentences
    Summary · context
    In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
    Summary · context
    CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix.
    Summary · context
    PSA and FSH levels were evaluated in CS21A for 3 months after cross-over.
  4. 04HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients, rapid FSH suppression persisted with degarelix in the comparative and extension studies.

    In plain wordsIn prostate cancer patients, FSH decreased rapidly and remained suppressed with degarelix.

    Peptide
    Degarelix
    Outcome
    DecreaseFSH suppression
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Rapid PSA and FSH suppression was observed and maintained in the degarelix arm (CS21 and CS21A), while patients on leuprolide experienced rising PSA during CS21.
    3 context sentences
    Summary · context
    In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
    Summary · context
    CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix.
    Summary · context
    PSA and FSH levels were evaluated in CS21A for 3 months after cross-over.
  5. 05HumanObservational studyMechanism

    In prostate cancer patients receiving degarelix, PSA and FSH levels correlated significantly at months 1, 3, 6, 12 and 13.

    In plain wordsIn prostate cancer patients receiving degarelix, PSA and FSH levels correlated at the reported months.

    Peptide
    Degarelix
    Outcome
    Not applicablePSA and FSH correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PSA and FSH levels were significantly (p < .05) correlated at months 1, 3, 6, 12 and 13 in the degarelix arm.
    3 context sentences
    Summary · context
    In this post-hoc analysis, FSH and prostate specific antigen (PSA) responses and the impact of cross-over from leuprolide to degarelix were evaluated from a 1-year comparative study (CS21) and its extension study (CS21A).
    Summary · context
    CS21A evaluated 386 patients, including those previously treated with degarelix (n = 251) who continued to receive degarelix, and those previously treated with leuprolide (n = 135) who crossed-over to receive degarelix.
    Summary · context
    PSA and FSH levels were evaluated in CS21A for 3 months after cross-over.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.